Axonics today announced its R20 rechargeable sacral neuromodulation (SNM) system has received CE Mark approval for use in adults with overactive bladder and/or fecal incontinence. The implant can last ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...
Boston Scientific has closed on its $3.7 billion acquisition of Axonics. The Marlborough, MA-based company first announced the deal in January. Axonics develops devices to treat urinary and bowel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback